Effect of Metformin on the Prognosis of Gastric Cancer Patients with Type 2 Diabetes Mellitus: A Meta-Analysis Based on Retrospective Cohort Studies

Lingna Li; Jianing Huang; Tongmin Huang; Jie Yao; Yeyuan Zhang; Meiling Chen; Haojie Shentu; Haiying Lou

doi:10.1155/2023/5892731

Effect of Metformin on the Prognosis of Gastric Cancer Patients with Type 2 Diabetes Mellitus: A Meta-Analysis Based on Retrospective Cohort Studies

Int J Endocrinol. 2023 Mar 4:2023:5892731. doi: 10.1155/2023/5892731. eCollection 2023.

Authors

Lingna Li¹, Jianing Huang², Tongmin Huang³, Jie Yao², Yeyuan Zhang², Meiling Chen², Haojie Shentu⁴, Haiying Lou⁵

Affiliations

¹ Pharmacy Department, The Affiliated Hospital of Ningbo University, Li Huili Hospital, Ningbo, China.
² School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
³ The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
⁴ School of Medical Imaging, Hangzhou Medical College, Hangzhou, Zhejiang, China.
⁵ Department of Endocrinology, Zhuji People's Hospital, Shaoxing, Zhejiang, China.

Abstract

Background: Metformin is one of the most common drugs for type 2 diabetes mellitus (T2DM) treatment. In addition, metformin intends to have a positive effect on the prognosis of several cancers. However, the therapeutic effect of metformin on gastric cancer (GC) remains controversial. This study explores and updates the therapeutic effect of metformin in GC patients with T2DM.

Methods: We searched through PubMed, Embase, Web of Science, and the Cochrane Library for relevant articles by July 2022. The relationship between metformin therapy and the prognosis of GC patients with T2DM was evaluated based on the hazard ratio (HR) at a 95% confidence interval (95% CI). Overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) were the primary outcomes analyzed.

Results: Seven retrospective cohort studies with a combined 2,858 patients met the inclusion criteria. OS and CSS were reported in six studies, and PFS was reported in four studies. Pooled results showed that, compared to the nonmetformin group, the prolonged OS (HR = 0.72, p = 0.001), CSS (HR = 0.81, p = 0.001), and PFS (HR = 0.70, p = 0.008) of the experimental group may be associated with the exposure to metformin.

Conclusion: Metformin may have a beneficial effect on the prognosis of GC patients with T2DM.